BioAtla IPO Presentation Deck

Type ADC Robust Pipeline of Antibody-Based Therapeutics CAB Program CTLA-4 Bispecific Bispecific BA3011 AXL (AXL-ADC) Positive BA3021 ROR2 (ROR2-ADC) Positive BA3071 (CTLA-4) Target BA3182 (Bispecific) CTLA-4 EGFR (Bispecific) EpCAM / CD3 BA3142 87-H3 (Bispecific) / CD3 Target EGFR /CD3 Nectin-4 (Bispecific) /CD3 Nectin-4 Indications Research and Discovery Product Candidates Туре CAB Program Indications STS & Bone Sarcoma, NSCLC, Ovarian Cancer (Mono & Combo w/ PD-1) NSCLC, Melanoma, Ovarian Cancer (Mono & Combo w/ PD-1) RCC, NSCLC, SCLC, HCC, Melanoma, Bladder, Gastric, Cervical Cancer (Mono & Combo w/ PD-1) NSCLC, SCLC, Colorectal, Ovarian, TNBC, Prostate Cancer** NSCLC, SCLC, HNC, Melanoma, Sarcoma, Pancreatic, Prostate Cancer** NSCLC, HNC, Pancreatic, TNBC, Colorectal Cancer** Bladder, TNBC, Pancreatic Cancer** Discovery Discovery IND Enabling IND Enabling Phase 1 Phase 1 Phase 2 BeiGene Phase 2 Phase 3 Phase 3 H Expected Upcoming ■ " H " I bicatla Milestones H Ph2 interim data 2021 Ph2 registration data 2022 H Ph1 dose escalation trial to be initiated in 2021 Ph2 interim data 2021 Ph2 registration data 2022 US IND in 1H 2022 US IND In 2022 Expected Upcoming Milestones US IND in 2022 " US IND In 2022 Abbreviations: STS = Soft Tissua Sarcoma, NSCLC = Non-small Call Lung Cancer, RCC = Renal Call Carcinoma, SCLC = Small Call Lung Cancer, HCC = Hapatocellular Carcinoma, TNBC = Triple- Negative Breast Cancer, HWC-Head and Neck Cancer: "Ph2 investigator initiated trial for Ovarian Cancer expected to be initiated by the end of 2020 or early 2021 ** Anticipated indications based upon tumor target expression 7

View entire presentation